The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Mino‐Kenudson, Mari; Stang, Nolwenn Le; Daigneault, Jillian B.; Nicholson, Andrew G.; Cooper, Wendy A.; Roden, Anja C.; Moreira, André L.; Thunnissen, Erik; Papotti, Mauro; Pelosi, Giuseppe; Motoi, Noriko; Poleri, Claudia; Brambilla, Élisabeth; Redman, Mary W.; Jain, Deepali; Đačić, Sanja; Yatabe, Yasushi; Tsao, Ming Sound; López‐Ríos, Fernando; Botling, Johan; Chen, Gang; Chou, Teh Ying; Hirsch, Fred R.; Beasley, Mary Beth; Bubendorf, Lukas; Chung, Jin Haeng; Hwang, David; Lin, Dongmei; Longshore, John; Noguchi, Masayuki; Rekhtman, Natasha; Sholl, Lynette M.; Travis, William D.; Yoshida, Akihiko; Wynes, Murry W.; Wistuba, Ignacio I.; Kerr, Keith M.; Lantuéjoul, Sylvie

doi:10.1016/j.jtho.2020.12.026

Cited by 15 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence and mortality of lung cancer ranks first among tumors, of which about 85% are non-small-cell lung cancer (NSCLC) [ 1 , 2 ]. Due to the high degree of malignancy, the 5-year survival rate was only 18.4%.…”

Section: Introductionmentioning

confidence: 99%

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Objective. To explore the expression and clinical significance of HER2 and DNMT1 in non-small-cell lung cancer. Methods. The patients with non-small-cell lung cancer treated in the First Affiliated Hospital of Jiamusi University between 2018 and 2020 were enrolled in this study. The serum DNMT1 concentration and the expression of HER2 protein in lung cancer and adjacent tissues of the two groups were analyzed. Results. The DNMT1 protein concentration was significantly correlated with gender, age, and smoking history of patients. HER2-positive expression was significantly related to tumor type, tumor size, tumor differentiation degree, and lymph node metastasis. However, HER2 levels were not related to the gender and smoking history of patients. Conclusion. High expression of DNMT1 protein in serum may increase the risk of non-small-cell lung cancer and may play an important role in the early development of lung cancer. HER2-positive expression may promote the development of advanced and metastatic non-small-cell lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…9 As the rate of negative cases in our prospective series of head and neck squamous cell carcinoma cases is comparable to that seen in the KEYNOTE-048 trial 4 and by Huang et al 20 when using the 22C3 antibody clone, it is likely that our distribution of negative, low-positive, and high-positive cases will be similar to that seen in most practices irrespective of the antibody clone being used. Furthermore, as the 22C3 antibody clone and Dako IHC platform are not used by a significant proportion of laboratories performing PD-L1 IHC testing in North America, 24 it is likely that a large number of laboratories are using the widely available SP263 clone, which uses the Ventana platform.…”

Section: Resultsmentioning

confidence: 99%

Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma

Kaur

Kuchta

Watkin

et al. 2022

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Pembrolizumab is used in patients with metastatic head and neck squamous cell carcinoma contingent upon the programmed death ligand-1 (PD-L1) combined positive score (CPS). Objective.— To compare PD-L1 CPS scores derived from paired resected primary tumors (PTs) and lymph node metastases (LMs) in patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC). Design.— We identified 38 resected p16+ OPSCCs for which paired PTs and LMs were available. PD-L1 immunohistochemistry using the SP263 antibody clone was done on both the PT and the LM. CPS scoring was performed by 4 observers and data were analyzed at the CPS cut points of greater than or equal to 1 and 20 in regard to interobserver and interspecimen agreement. Results.— Overall agreement between consensus CPS scoring of PT and LM was seen in 76% of paired specimens (κ = 0.53). No specimen received a negative consensus score. Interobserver agreement for both PT and LM was fair to substantial (κ = 0.54 and 0.51, respectively) and was inferior to that seen in a prospective series of unselected head and neck squamous carcinoma cases evaluated at our institution (κ = 0.84). Conclusions.— Given the high rates of interobserver and interspecimen variability, evaluation of additional material or by additional observers may be of value in performing CPS scoring in cases of p16+ OPSCC. This is particularly the case when a negative or low-positive result is being evaluated in a patient who is otherwise a good candidate for immunotherapy.

show abstract

“…PD‐L1 expression, which is not assessed by NGS testing, should be assessed by immunohistochemical staining in all patients with advanced NSCLC, regardless of histology. Assessing PD‐L1 expression has its own issues, including heterogeneity in expression across a tumor and over time, selecting predictive cutoff values, concordance of different assays, and interpretations between pathologists 18–20 . Laboratories should adhere to sample requirements, including evaluation of a minimum of 100 tumor cells; given the impact of cold ischemia time, fixation duration and type, and age of the specimen on antigenicity, adherence to strict protocols on the part of proceduralists and laboratorians is essential to reduce the risk of false‐negative results 21–23 .…”

Section: Rationale For Comprehensive Biomarker Testing For Patients W...mentioning

confidence: 99%

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best‐practice guide

Nishino

Osarogiagbon²,

Rivera

et al. 2023

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Advances in biomarker‐driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker‐driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time‐sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.

show abstract

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Cited by 15 publications

References 40 publications

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer

Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best‐practice guide

Contact Info

Product

Resources

About